Physician profile
Whitney B Atha
NPI 1790108348
$553.56
in general payments reported to CMS, 2019-2025
15 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.96 · 2023: $148 · 2024: $203 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $127.68 | 2024-2025 | |
| Novo Nordisk INC | $65.96 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Boston Scientific Corporation | $55.09 | 2025 | Farapulse, Watchman Flx |
| Glaxosmithkline, LLC. | $47.74 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $46.47 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $44.90 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $40.28 | 2021-2024 | Farxiga |
| Supernus Pharmaceuticals, INC. | $22.66 | 2021 | |
| Exact Sciences Corporation | $21.94 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.85 | 2024 | Voquezna |
| Amgen INC. | $15.53 | 2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.75 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.49 | 2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $13.16 | 2023 | Jardiance |
| Organon LLC | $7.06 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Atha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.